Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katharine Abbott

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Pulmonary Pharmacology & Therapeutics|June 17, 2019
Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthmaLeif Bjermer, Katharine Abbott-Banner, Kenneth Newman
Current Topics in Medicinal Chemistry|March 20, 2013
Targeting TRP channels in airway disordersKatharine Abbott-Banner, Christopher Poll, J Martin Verkuyl
The European Respiratory Journal|September 1, 2018
The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPDDave Singh, Katharine Abbott-Banner, Thomas Bengtsson, et al.
Clinical Science (London, England : 1979)|October 21, 2014
Translational models of lung diseasePaul F Mercer, Katharine Abbott-Banner, Ian M Adcock, et al.
Nursing Open|January 12, 2023
Hospital practitioner views on the benefits of continence education and best ways to provide trainingJohn Percival, Katharine Abbott, Theresa Allain, et al.
BMJ Open Quality|April 10, 2021
'We tend to get pad happy': a qualitative study of health practitioners' perspectives on the quality of continence care for older people in hospitalJohn Percival, Katharine Abbott, Theresa Allain, et al.
Annals of the Rheumatic Diseases|October 17, 2024
Efficacy, safety and tolerability of GSK3858279, an anti-CCL17 monoclonal antibody and analgesic, in healthy volunteers and patients with knee osteoarthritis pain: a phase I, randomised, double-blind, placebo-controlled, proof-of-mechanism and proof-of-concept studyJagtar Singh Nijjar, Katharine Abbott-Banner, Yolanda Alvarez, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Pulmonary Pharmacology & Therapeutics|June 17, 2019
Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthmaLeif Bjermer, Katharine Abbott-Banner, Kenneth Newman
Current Topics in Medicinal Chemistry|March 20, 2013
Targeting TRP channels in airway disordersKatharine Abbott-Banner, Christopher Poll, J Martin Verkuyl
The European Respiratory Journal|September 1, 2018
The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPDDave Singh, Katharine Abbott-Banner, Thomas Bengtsson, et al.
Clinical Science (London, England : 1979)|October 21, 2014
Translational models of lung diseasePaul F Mercer, Katharine Abbott-Banner, Ian M Adcock, et al.
Nursing Open|January 12, 2023
Hospital practitioner views on the benefits of continence education and best ways to provide trainingJohn Percival, Katharine Abbott, Theresa Allain, et al.
BMJ Open Quality|April 10, 2021
'We tend to get pad happy': a qualitative study of health practitioners' perspectives on the quality of continence care for older people in hospitalJohn Percival, Katharine Abbott, Theresa Allain, et al.
Annals of the Rheumatic Diseases|October 17, 2024
Efficacy, safety and tolerability of GSK3858279, an anti-CCL17 monoclonal antibody and analgesic, in healthy volunteers and patients with knee osteoarthritis pain: a phase I, randomised, double-blind, placebo-controlled, proof-of-mechanism and proof-of-concept studyJagtar Singh Nijjar, Katharine Abbott-Banner, Yolanda Alvarez, et al.
Pageof 1